Talis Biomedical Corporation (TLIS)
NASDAQ: TLIS · IEX Real-Time Price · USD
8.50
+0.07 (0.83%)
Jul 2, 2024, 4:30 PM EDT - Market closed

Talis Biomedical Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year
Current2023202220212020
Market Capitalization
152825225-
Market Cap Growth
20.02%12.49%-88.79%--
Enterprise Value
-36-29-717-172
PE Ratio
--0.46-0.22-1.17-
PS Ratio
15.6613.315.2527.48-
PB Ratio
0.270.410.200.96-
P/FCF Ratio
-0.76-0.53-0.25-1.29-
P/OCF Ratio
-0.77-0.53-0.25-1.31-
EV/Sales Ratio
-17.93-13.43-14.830.81-15.77
EV/EBITDA Ratio
0.340.500.70-0.031.92
EV/EBIT Ratio
0.310.460.63-0.031.89
EV/FCF Ratio
0.410.530.70-0.041.81
Debt / Equity Ratio
0.340.280.260.06-0.01
Debt / EBITDA Ratio
-0.37-0.35-0.33-0.07-0.01
Debt / FCF Ratio
-0.44-0.37-0.33-0.08-0.01
Quick Ratio
7.438.7510.3012.1810.83
Current Ratio
7.528.8610.5212.3611.77
Asset Turnover
0.010.020.020.020.10
Return on Equity (ROE)
-75.40%-69.50%-68.60%-67.20%140.50%
Return on Assets (ROA)
-56.20%-54.20%-55.40%-56.80%-81.30%
Return on Capital (ROIC)
-81.57%-75.26%-71.82%-77.36%84.53%
Earnings Yield
-369.38%-218.34%-447.63%-85.28%-
FCF Yield
-281.72%-189.18%-403.02%-77.39%-
Buyback Yield / Dilution
-0.51%-0.95%-19.21%-968.49%1.41%
Total Shareholder Return
-0.51%-0.95%-19.21%-968.49%1.41%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).